HeartSciences Signs Agreement with St. Vincent Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy HSCS?
HeartSciences announced that it has signed a commercial agreement with St. Vincent Health to deploy the MyoVista Insights platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSCS
Wall Street analysts forecast HSCS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.940
Low
9.20
Averages
10.60
High
12.00
Current: 1.940
Low
9.20
Averages
10.60
High
12.00
No data
About HSCS
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HeartSciences Achieves Epic Toolbox Designation for MyoVista Insights
- Platform Certification: HeartSciences' MyoVista Insights™ platform has received Epic Toolbox designation, marking a significant milestone in the ECG management system sector and enhancing the company's competitiveness in the healthcare IT market.
- Integration Capabilities: The platform supports integration with hospital information systems and electronic health records (EHRs) using HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR, ensuring clinicians can seamlessly access MyoVista Insights™ within existing workflows.
- Clinical Decision Support: MyoVista Insights™ is designed to enhance workflow efficiency and support clinical decision-making, which is expected to improve healthcare providers' workflows, thereby enhancing patient care quality and efficiency.
- Strategic Expansion: CEO Andrew Simpson stated that this certification is a crucial part of the company's interoperability strategy aimed at expanding access to MyoVista Insights™ across healthcare systems, driving future market growth.
See More
Heart Test Laboratories Q3 Earnings Beat Expectations
- Earnings Surprise: Heart Test Laboratories reported a Q3 GAAP EPS of -$0.63, beating market expectations by $0.19, indicating the company's resilience in challenging conditions.
- Cash Position: The company holds $3.4 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operational and investment needs.
- Shareholder Equity Insight: With shareholders' equity at $2.7 million, the company shows stability in its capital structure, maintaining a healthy balance sheet despite ongoing profitability challenges.
- Market Reaction Outlook: Following the earnings release, market interest in Heart Test Laboratories may increase, with investors closely monitoring its future financial performance and strategic direction.
See More
HeartSciences Partners with Cibolo Health for ECG Management
- Partnership Agreement: HeartSciences has partnered with Cibolo Rural Health Networks, selecting MyoVista Insights™ as the endorsed ECG management platform for 123 independent hospitals, enhancing healthcare quality and efficiency.
- Technology Integration: With MyoVista Insights, Cibolo Health's hospitals will modernize ECG workflows, enabling physicians to interpret ECGs more quickly and efficiently, thereby improving clinical decision-making processes.
- Cloud Platform Advantages: MyoVista Insights offers secure cloud-based ECG data management, supporting various devices and file formats, ensuring regulatory-compliant AI-ECG algorithms can be integrated into routine clinical practice, enhancing accessibility to healthcare services.
- Strategic Implications: This collaboration aligns with Cibolo Health's mission to optimize care delivery while also driving HeartSciences' market expansion within high-value networks, strengthening its competitive position in the healthcare information technology sector.
See More
HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology
- Product Advancement: HeartSciences submitted its MyoVista® wavECG™ device to the FDA for 510(k) clearance at the end of its fiscal second quarter on October 31, 2025, marking a significant regulatory milestone that is expected to accelerate the product's market entry.
- Software Platform Validation: Since its launch in May 2025, the MyoVista Insights™ platform has received strong validation from early adopters and is currently engaged in commercial discussions with several healthcare institutions, with multiple key customer wins expected to be announced soon, further driving revenue growth.
- Market Opportunity: As a Medical Device Data System, MyoVista Insights carries significantly lower regulatory requirements, which is anticipated to substantially reduce the costs and speed of commercial rollout, enabling the company to quickly tap into a multibillion-dollar market opportunity.
- Financial Position: As of October 31, 2025, HeartSciences reported approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity, and while no meaningful revenue was generated in FQ2 2026, the company is actively advancing its commercialization strategy.
See More
HeartSciences Submits MyoVista Device for FDA 510(k) Clearance
- Regulatory Milestone: HeartSciences has submitted its MyoVista wavECG device for FDA 510(k) clearance, aiming to expedite the regulatory review process, which is expected to enhance the company's competitiveness in the healthcare IT sector.
- Technological Innovation: The device not only provides conventional ECG functionality but also supports AI-ECG algorithms, aligning with the latest ASE guidelines for LVDD assessment, which is anticipated to improve clinical decision-making and patient care quality.
- Flexible Development Strategy: The company opted to separate the FDA submissions for the device and the AI-ECG software algorithm to simplify the regulatory pathway and accelerate device clearance while preserving flexibility for future AI-ECG deployments, enhancing market adaptability.
- Market Expansion Potential: CEO Andrew Simpson noted that progress with the MyoVista Insights platform is occurring in parallel with the device submission, with initial customer deployments expected to be announced soon as commercial discussions with several healthcare institutions advance, further driving revenue growth.
See More
Ascendiant Capital Reaffirms Buy Rating on HeartSciences, Reduces Price Target to $9
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
HeartSciences Achieves Epic Toolbox Designation for MyoVista Insights
- Platform Certification: HeartSciences' MyoVista Insights™ platform has received Epic Toolbox designation, marking a significant milestone in the ECG management system sector and enhancing the company's competitiveness in the healthcare IT market.
- Integration Capabilities: The platform supports integration with hospital information systems and electronic health records (EHRs) using HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR, ensuring clinicians can seamlessly access MyoVista Insights™ within existing workflows.
- Clinical Decision Support: MyoVista Insights™ is designed to enhance workflow efficiency and support clinical decision-making, which is expected to improve healthcare providers' workflows, thereby enhancing patient care quality and efficiency.
- Strategic Expansion: CEO Andrew Simpson stated that this certification is a crucial part of the company's interoperability strategy aimed at expanding access to MyoVista Insights™ across healthcare systems, driving future market growth.
See More
Heart Test Laboratories Q3 Earnings Beat Expectations
- Earnings Surprise: Heart Test Laboratories reported a Q3 GAAP EPS of -$0.63, beating market expectations by $0.19, indicating the company's resilience in challenging conditions.
- Cash Position: The company holds $3.4 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operational and investment needs.
- Shareholder Equity Insight: With shareholders' equity at $2.7 million, the company shows stability in its capital structure, maintaining a healthy balance sheet despite ongoing profitability challenges.
- Market Reaction Outlook: Following the earnings release, market interest in Heart Test Laboratories may increase, with investors closely monitoring its future financial performance and strategic direction.
See More
HeartSciences Partners with Cibolo Health for ECG Management
- Partnership Agreement: HeartSciences has partnered with Cibolo Rural Health Networks, selecting MyoVista Insights™ as the endorsed ECG management platform for 123 independent hospitals, enhancing healthcare quality and efficiency.
- Technology Integration: With MyoVista Insights, Cibolo Health's hospitals will modernize ECG workflows, enabling physicians to interpret ECGs more quickly and efficiently, thereby improving clinical decision-making processes.
- Cloud Platform Advantages: MyoVista Insights offers secure cloud-based ECG data management, supporting various devices and file formats, ensuring regulatory-compliant AI-ECG algorithms can be integrated into routine clinical practice, enhancing accessibility to healthcare services.
- Strategic Implications: This collaboration aligns with Cibolo Health's mission to optimize care delivery while also driving HeartSciences' market expansion within high-value networks, strengthening its competitive position in the healthcare information technology sector.
See More
HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology
- Product Advancement: HeartSciences submitted its MyoVista® wavECG™ device to the FDA for 510(k) clearance at the end of its fiscal second quarter on October 31, 2025, marking a significant regulatory milestone that is expected to accelerate the product's market entry.
- Software Platform Validation: Since its launch in May 2025, the MyoVista Insights™ platform has received strong validation from early adopters and is currently engaged in commercial discussions with several healthcare institutions, with multiple key customer wins expected to be announced soon, further driving revenue growth.
- Market Opportunity: As a Medical Device Data System, MyoVista Insights carries significantly lower regulatory requirements, which is anticipated to substantially reduce the costs and speed of commercial rollout, enabling the company to quickly tap into a multibillion-dollar market opportunity.
- Financial Position: As of October 31, 2025, HeartSciences reported approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity, and while no meaningful revenue was generated in FQ2 2026, the company is actively advancing its commercialization strategy.
See More
HeartSciences Submits MyoVista Device for FDA 510(k) Clearance
- Regulatory Milestone: HeartSciences has submitted its MyoVista wavECG device for FDA 510(k) clearance, aiming to expedite the regulatory review process, which is expected to enhance the company's competitiveness in the healthcare IT sector.
- Technological Innovation: The device not only provides conventional ECG functionality but also supports AI-ECG algorithms, aligning with the latest ASE guidelines for LVDD assessment, which is anticipated to improve clinical decision-making and patient care quality.
- Flexible Development Strategy: The company opted to separate the FDA submissions for the device and the AI-ECG software algorithm to simplify the regulatory pathway and accelerate device clearance while preserving flexibility for future AI-ECG deployments, enhancing market adaptability.
- Market Expansion Potential: CEO Andrew Simpson noted that progress with the MyoVista Insights platform is occurring in parallel with the device submission, with initial customer deployments expected to be announced soon as commercial discussions with several healthcare institutions advance, further driving revenue growth.
See More
Ascendiant Capital Reaffirms Buy Rating on HeartSciences, Reduces Price Target to $9
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
